HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ianalumab

B cell-depleting, B cell activating factor receptor-blocking, monoclonal antibody

Also Known As:

VAY736

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Dörner, Thomas: 2 articles (01/2022 - 01/2019)
2.	Barcelos, Filipe: 1 article (01/2022)
3.	Bowman, Simon J: 1 article (01/2022)
4.	De Vita, Salvatore: 1 article (01/2022)
5.	Fisher, Benjamin A: 1 article (01/2022)
6.	Fox, Robert: 1 article (01/2022)
7.	Grader-Beck, Thomas: 1 article (01/2022)
8.	Hueber, Wolfgang: 1 article (01/2022)
9.	Junge, Guido: 1 article (01/2022)
10.	Luo, Wen-Lin: 1 article (01/2022)

Related Diseases

1.	Sjogren's Syndrome (Sjogren Syndrome) 11/01/2020 - "Although early in development, the promising results in Sjogren's syndrome with iscalimab and ianalumab should make the Sjogren's syndrome community quite hopeful of future drug approvals. "
2.	Pneumonia (Pneumonitis) 01/01/2022 - "There were four serious adverse events in three patients considered treatment-related (pneumonia [n=1] and gastroenteritis [n=1] in the placebo group; appendicitis plus tubo-ovarian abscess in the same patient in the ianalumab 50 mg group). "
3.	Infections 01/01/2022 - "Overall, ianalumab was well tolerated and safe, with no increase in infections. "
4.	Gastroenteritis 01/01/2022 - "There were four serious adverse events in three patients considered treatment-related (pneumonia [n=1] and gastroenteritis [n=1] in the placebo group; appendicitis plus tubo-ovarian abscess in the same patient in the ianalumab 50 mg group). "
5.	Fatigue 01/01/2019 - "A similar trend showing positive therapeutic effect by ianalumab was observed across the primary clinical outcome (ESSDAI) and all secondary clinical outcomes (ESSPRI, Multidimensional Fatigue Inventory, Short Form-36, global assessments by physician and patient) versus the placebo-treated group. "

Related Drugs and Biologics

1.	iscalimab
2.	Therapeutic Uses